Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib combined with etanercept for corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation
ChiCTR1900024408Phase 4Completed
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jan 2017
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ruxolitinib and etanercept in graft-versus-host disease (GVHD), Acute Graft-Versus-Host Disease (aGvHD) and chronic graft-versus-host disease (cGVHD), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Safety and Overall survival. Started Jan 2017; status: completed.
02
Drugs
ruxolitinibetanercept
03
Conditions
graft-versus-host disease (GVHD)Acute Graft-Versus-Host Disease (aGvHD)chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on ChiCTR1900024408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024408.